Dihexa
Preclinical ResearchDihexa
A highly experimental synthetic derivative of angiotensin IV studied for nootropic and neuroprotective effects. Evidence is largely preclinical.
Dose
10-50 mg
Route
Oral, Topical, SubQ injection
Cycle
4-8 weeks
Storage
Refrigerated (2-8°C)
What is Dihexa?
Dihexa is a highly potent synthetic derivative of Angiotensin IV, known for its significant nootropic and neuroprotective properties. Research indicates it is a potent activator of the HGF/MET receptor system, crucial for neurogenesis and synaptogenesis. Studies have suggested that Dihexa is vastly more potent than BDNF in promoting synapse formation in animal models. Its primary research interest lies in its potential to enhance cognitive function, improve memory, and offer neuroprotection against various neurological disorders, including Alzheimer's disease. It has been explored for oral, topical, and subcutaneous administration routes in research settings.
Key Benefits
- Synaptogenesis (new synapse formation)
- Cognitive enhancement
- Memory improvement
- Alzheimer's research potential
- Neuroprotection
Mechanism of Action
- HGF/MET receptor activation
- Promotes synapse formation
- Reported 10 million times more potent than BDNF in animal models
Best For
- Advanced cognitive research
- Neuroprotection research
- Memory research
Body Systems
🐾 Griffin Says...
Molecular Information
Molecular weight
473.5 g/mol
Type
Synthetic Hexapeptide Analog
Amino acid sequence
Phe-Ala-Asp-Gly-Leu-Gly
A derivative of Angiotensin IV, modified for enhanced stability and activity.
Research Indications
Synaptogenesis
Promotes the formation of new synapses, crucial for learning and memory, reported to be significantly more potent than BDNF.
Memory Improvement
In animal models, Dihexa has shown promising effects in enhancing both short-term and long-term memory.
Learning Capacity
May improve the ability to acquire and process new information, suggesting potential benefits for learning.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Cognitive Enhancement (Subcutaneous) | 10-20 mg | Once daily, 5 days on, 2 days off | Subcutaneous injection |
| Neuroprotection/Synaptogenesis (Subcutaneous) | 20-30 mg | Three times per week (e.g., Mon/Wed/Fri) | Subcutaneous injection |
| Exploratory Oral Administration | 20-50 mg | Once daily | Oral |
| Exploratory Topical Application | Concentration typically 0.5% - 2% | Once or twice daily | Topical |
| Aggressive Cognitive Enhancement (Subcutaneous) | 30-50 mg | Once daily | Subcutaneous injection |
Timing of administration may vary based on individual research goals and observed effects. Morning administration is common to potentially align with daily cognitive demands, while evening administration may be considered for neuroregenerative processes.
Peptide Interactions
- Synergistic
BDNF (Brain-Derived Neurotrophic Factor)
Dihexa's mechanism of action, involving HGF/MET activation and synaptogenesis, is complementary to BDNF's role in neuronal growth and survival. Some research indicates Dihexa's activity may be downstream or additive to BDNF pathways.
- Monitor Combination
Other Nootropics (e.g., Modafinil, Phenylpiracetam)
Combination with other potent cognitive enhancers may lead to additive effects or potential overstimulation. Careful observation of individual responses is advised.
- Use Caution
CNS Depressants (e.g., Alcohol, Benzodiazepines)
Dihexa's impact on central nervous system function could theoretically alter the effects of depressants. Concurrent use should be approached with extreme caution and monitoring.
- Monitor Combination
Angiotensin II Receptor Blockers (ARBs)
As a derivative of Angiotensin IV, there is theoretical potential for interaction with drugs affecting the renin-angiotensin system. This is largely speculative and requires further research.
- Compatible
Growth Factors (e.g., IGF-1, FGF-2)
Dihexa's HGF/MET activation pathway is distinct but can complement the neurotrophic effects of other growth factors. No adverse interactions are typically discussed.
How to Reconstitute
- 1Gather materials: Dihexa vial, sterile bacteriostatic water for injection, sterile syringe, and alcohol wipes.
- 2Wipe the tops of both the Dihexa vial and the bacteriostatic water vial with alcohol wipes.
- 3Draw the desired amount of bacteriostatic water (e.g., 1 mL for a 50 mg vial) into the sterile syringe.
- 4Slowly inject the bacteriostatic water into the Dihexa vial, directing it down the side of the vial to avoid direct contact with the peptide powder.
- 5Gently swirl the vial (do not shake) until the powder is fully dissolved. This may take a few minutes.
- 6Store the reconstituted solution in the refrigerator.
For subcutaneous administration, reconstitution should be performed carefully to maintain sterility and peptide integrity.
What to Expect
- Weeks 1-2: Some researchers report initial subtle cognitive improvements, such as enhanced focus or clarity.
- Weeks 2-4: More noticeable cognitive benefits, including improved memory recall and learning capacity, may be observed.
- Weeks 4-8: Sustained cognitive enhancement, potential improvements in mood, and overall neuroprotective effects are commonly discussed.
- Beyond 8 weeks (after a break): Re-evaluation of research goals and consideration of further cycles if warranted by observations.
Side Effects & Safety
| Effect | Frequency | Severity |
|---|---|---|
| Unknown long-term profile | Unknown | Unknown |
| Potential anxiety or agitation at high doses | Anecdotal | Mild |
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.